AAAAAA

   
Results: 1-7 |
Results: 7
Design, synthesis and pharmacological characterization of a potent radioiodinated and photoactivatable peptidic oxytocin antagonist
Authors: Carnazzi, E Aumelas, A Mouillac, B Breton, C Guillou, L Barberis, C Seyer, R
Citation: E. Carnazzi et al., Design, synthesis and pharmacological characterization of a potent radioiodinated and photoactivatable peptidic oxytocin antagonist, J MED CHEM, 44(18), 2001, pp. 3022-3030
Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist - Comparison with the human V-1a vasopressin receptor
Authors: Breton, C Chellil, H Kabbaj-Benmansour, M Carnazzi, E Seyer, R Phalipou, S Morin, D Durroux, T Zingg, H Barberis, C Mouillac, B
Citation: C. Breton et al., Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist - Comparison with the human V-1a vasopressin receptor, J BIOL CHEM, 276(29), 2001, pp. 26931-26941
Conserved aromatic residues in the transmembrane region VI of the V-1a vasopressin receptor differentiate agonist vs. antagonist ligand binding
Authors: Cotte, N Balestre, MN Aumelas, A Mahe, E Phalipou, S Morin, D Hibert, M Manning, M Durroux, T Barberis, C Mouillac, B
Citation: N. Cotte et al., Conserved aromatic residues in the transmembrane region VI of the V-1a vasopressin receptor differentiate agonist vs. antagonist ligand binding, EUR J BIOCH, 267(13), 2000, pp. 4253-4263
Functional architecture of vasopressin/oxytocin receptors
Authors: Hibert, M Hoflack, J Trumpp-Kallmeyer, S Mouillac, B Chini, B Mahe, E Cotte, N Jard, S Manning, M Barberis, C
Citation: M. Hibert et al., Functional architecture of vasopressin/oxytocin receptors, J RECEPT SI, 19(1-4), 1999, pp. 589-596
Docking of linear peptide antagonists into the human V-1a vasopressin receptor - Identification of binding domains by photoaffinity labeling
Authors: Phalipou, S Seyer, R Cotte, N Breton, C Barberis, C Hibert, M Mouillac, B
Citation: S. Phalipou et al., Docking of linear peptide antagonists into the human V-1a vasopressin receptor - Identification of binding domains by photoaffinity labeling, J BIOL CHEM, 274(33), 1999, pp. 23316-23327
The D136A mutation of the V-2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities
Authors: Morin, D Cotte, N Balestre, MN Mouillac, B Manning, M Breton, C Barberis, C
Citation: D. Morin et al., The D136A mutation of the V-2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities, FEBS LETTER, 441(3), 1998, pp. 470-475
The vasopressin V2 receptor: molecular basis of the nephrogenic diabetes insipidus and identification of residues responsible for binding selectivity
Authors: Morin, D Cotte, N Phalipou, S Balestre, MN Ala, Y Sabatier, N Jard, S Vargas, R Antignac, C Dechaux, M Arthus, M Lonergan, M Turner, MS Bichet, DG Hendy, GN Alonso, G Manning, M Hibert, M Mouillac, B Barberis, C
Citation: D. Morin et al., The vasopressin V2 receptor: molecular basis of the nephrogenic diabetes insipidus and identification of residues responsible for binding selectivity, HYDRATION THROUGHOUT LIFE, 1998, pp. 215-221
Risultati: 1-7 |